Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.

Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, Melosky B, Tran D, Boehm D, Venkatesh J, Walisser S, Orava E, Grima D.

Lung Cancer. 2020 Jan;139:185-194. doi: 10.1016/j.lungcan.2019.10.019. Epub 2019 Oct 22.

2.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
3.

Fulfilling the potential of real-world evidence for lung cancer in Canada.

Cheema PK, Kuruvilla S.

Curr Oncol. 2019 Jun;26(3):157-159. doi: 10.3747/co.26.5151. Epub 2019 Jun 1. No abstract available.

4.

A network approach to developing immuno-oncology combinations in Canada.

Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S.

Curr Oncol. 2019 Apr;26(2):73-79. doi: 10.3747/co.26.4393. Epub 2019 Apr 1.

5.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS.

Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.

6.

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.

Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V.

Curr Oncol. 2019 Feb;26(1):37-42. doi: 10.3747/co.25.4096. Epub 2019 Feb 1. Review.

7.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

PMID:
30659024
8.

Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.

Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J.

Support Care Cancer. 2019 Mar;27(3):1029-1039. doi: 10.1007/s00520-018-4392-x. Epub 2018 Aug 16.

PMID:
30116943
9.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

10.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.

Cheema PK, Doherty M, Tsao MS.

J Thorac Oncol. 2017 Dec;12(12):e200-e202. doi: 10.1016/j.jtho.2017.07.033. No abstract available.

11.

Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.

Cheema PK, Raphael S, El-Maraghi R, Li J, McClure R, Zibdawi L, Chan A, Victor JC, Dolley A, Dziarmaga A.

Curr Oncol. 2017 Feb;24(1):16-22. doi: 10.3747/co.24.3266. Epub 2017 Feb 27.

12.

Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Cheema PK, Menjak IB, Winterton-Perks Z, Raphael S, Cheng SY, Verma S, Muinuddin A, Freedman R, Toor N, Perera J, Anaka M, Victor JC.

J Oncol Pract. 2017 Feb;13(2):e130-e138. doi: 10.1200/JOP.2016.014019. Epub 2016 Dec 28.

PMID:
28029301
13.

Personalizing health care: feasibility and future implications.

Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L, Nilsson F, Paterson K, Schwabe U, Selke G, Sermet C, Simoens S, Tomek D, Vlahovic-Palcevski V, Voncina L, Wladysiuk M, van Woerkom M, Wong-Rieger D, Zara C, Ali R, Gustafsson LL.

BMC Med. 2013 Aug 13;11:179. doi: 10.1186/1741-7015-11-179. Review.

14.

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.

Cheema PK, Burkes RL.

Curr Oncol. 2013 Apr;20(2):e150-60. doi: 10.3747/co.20.1226.

15.

International variability in the reimbursement of cancer drugs by publically funded drug programs.

Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME.

Curr Oncol. 2012 Jun;19(3):e165-76. doi: 10.3747/co.19.946.

16.

Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.

Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J.

Biol Blood Marrow Transplant. 2009 Jun;15(6):686-93. doi: 10.1016/j.bbmt.2009.02.013. Epub 2009 Apr 9.

Supplemental Content

Loading ...
Support Center